Acquisitions - Additional Information (Details) € in Millions											1 Months Ended	3 Months Ended			6 Months Ended					12 Months Ended
		Mar. 01, 2016 USD ($)	Jan. 22, 2016 USD ($)	Dec. 15, 2015 USD ($)	Sep. 15, 2015 USD ($)	Sep. 15, 2015 EUR (€)	Aug. 28, 2015 USD ($)	May 12, 2015 USD ($)	Mar. 30, 2015 USD ($) shares	Mar. 30, 2015 EUR (€) shares	May 31, 2015 USD ($)	Jul. 02, 2016 USD ($)		Jun. 27, 2015 USD ($)	Jul. 02, 2016 USD ($)		Dec. 31, 2015 USD ($)	Jun. 27, 2015 USD ($)		Dec. 31, 2015 USD ($) products	Jun. 27, 2015 USD ($) shares	Dec. 02, 2014 USD ($)	Nov. 08, 2013 USD ($)
Business Acquisition [Line Items]
Research and development												$ 47,000,000		$ 62,600,000	$ 92,200,000			$ 98,000,000
Senior notes												5,918,600,000			5,918,600,000		$ 4,698,300,000			$ 4,698,300,000			$ 2,300,000,000
Proceeds from stock issuance																					$ 999,300,000
Operating income (loss)												184,800,000		$ 192,300,000	(46,800,000)	[1]		$ 382,700,000	[1]
2014 bonds
Business Acquisition [Line Items]
Senior notes																						$ 1,600,000,000
Ordinary shares
Business Acquisition [Line Items]
Stock issued (in shares) | shares																					6,800,000
Contractual arrangement
Business Acquisition [Line Items]
Research and development											$ 18,000,000
Tretinoin Products
Business Acquisition [Line Items]
Acquisition date			Jan. 22, 2016
Purchase price paid			$ 416,400,000
Contingent consideration			$ 0
Net sales												13,400,000			29,200,000
Operating income (loss)												7,500,000			18,900,000
Tretinoin Products | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life			20 years
Tretinoin Products | Non-compete agreements
Business Acquisition [Line Items]
Intangible assets weighted average useful life			5 years
Development-Stage Rx Products
Business Acquisition [Line Items]
Acquisition date		Mar. 01, 2016
Purchase price paid	[2]	$ 0
Contingent consideration	[2]	$ 24,900,000
Development-Stage Rx Products | Minimum
Business Acquisition [Line Items]
Royalty payment period		7 years
Development-Stage Rx Products | Maximum
Business Acquisition [Line Items]
Royalty payment period		10 years
Entocort®
Business Acquisition [Line Items]
Acquisition date				Dec. 15, 2015
Purchase price paid				$ 380,200,000
Contingent consideration				$ 0
Entocort® | Minimum | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life				10 years
Entocort® | Maximum | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life				15 years
Naturwohl
Business Acquisition [Line Items]
Acquisition date					Sep. 15, 2015	Sep. 15, 2015
Purchase price paid					$ 150,400,000
Contingent consideration					$ 0
Percentage of interests acquired					100.00%
Naturwohl | Non-compete agreements
Business Acquisition [Line Items]
Intangible assets weighted average useful life					3 years	3 years
Naturwohl | Trademarks, trade names, and brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life					20 years	20 years
Naturwohl | Customer relationships and distribution networks
Business Acquisition [Line Items]
Intangible assets weighted average useful life					15 years	15 years
Naturwohl | Distribution and license agreements, supply agreements
Business Acquisition [Line Items]
Intangible assets weighted average useful life					3 years	3 years
Naturwohl | Euro
Business Acquisition [Line Items]
Purchase price paid | €						€ 133.5
ScarAway®
Business Acquisition [Line Items]
Acquisition date							Aug. 28, 2015
Purchase price paid							$ 26,700,000
Contingent consideration							$ 0
ScarAway® | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life							8 years
ScarAway® | Non-compete agreements
Business Acquisition [Line Items]
Intangible assets weighted average useful life							4 years
ScarAway® | Trademarks, trade names, and brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life							25 years
ScarAway® | Customer relationships and distribution networks
Business Acquisition [Line Items]
Intangible assets weighted average useful life							15 years
GSK Products
Business Acquisition [Line Items]
Acquisition date							Aug. 28, 2015
Purchase price paid							$ 223,600,000
Contingent consideration							$ 0
GSK Products | Trademarks, trade names, and brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life							20 years
GSK Products | Customer relationships and distribution networks
Business Acquisition [Line Items]
Intangible assets weighted average useful life							15 years
GSK Products | Euro
Business Acquisition [Line Items]
Purchase price paid							$ 200,000,000
Gelcaps
Business Acquisition [Line Items]
Acquisition date								May 12, 2015
Purchase price paid								$ 37,900,000
Contingent consideration								$ 0
Percentage of interests acquired								100.00%
Gelcaps | Trademarks, trade names, and brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life								25 years
Gelcaps | Customer relationships and distribution networks
Business Acquisition [Line Items]
Intangible assets weighted average useful life								20 years
Gelcaps | Inventory
Business Acquisition [Line Items]
Inventory adjustment								$ 600,000
Gelcaps | Property, plant and equipment
Business Acquisition [Line Items]
Property, plant and equipment adjustment								$ 900,000
Omega
Business Acquisition [Line Items]
Acquisition date									Mar. 30, 2015	Mar. 30, 2015
Purchase price paid									$ 2,983,200,000
Intangible assets weighted average useful life									20 years 7 months 6 days	20 years 7 months 6 days
Contingent consideration									$ 0
Percentage of interests acquired									95.77%
Shares outstanding (in shares) | shares									685,348,257
Treasury stock (in shares) | shares									30,243,983	30,243,983
Omega | Non-compete agreements
Business Acquisition [Line Items]
Intangible assets weighted average useful life									3 years	3 years
Omega | Trademarks, trade names, and brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life									8 years	8 years
Omega | Customer relationships and distribution networks
Business Acquisition [Line Items]
Intangible assets weighted average useful life									21 years	21 years
Omega | Non-solicit agreement
Business Acquisition [Line Items]
Intangible assets weighted average useful life									2 years	2 years
Omega | Brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life									22 years	22 years
Omega | Minimum | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life									4 years	4 years
Omega | Maximum
Business Acquisition [Line Items]
Indemnification available from acquired company's sellers | €										€ 277.0
Omega | Maximum | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life									13 years	13 years
Omega | Euro | Maximum
Business Acquisition [Line Items]
Indemnification available from acquired company's sellers									$ 248,000,000
Omega | Inventory
Business Acquisition [Line Items]
Inventory adjustment									15,100,000
Omega | Property, plant and equipment
Business Acquisition [Line Items]
Property, plant and equipment adjustment									41,500,000
Omega | Debt
Business Acquisition [Line Items]
Business combination fair value adjustment									$ 101,900,000
All Other
Business Acquisition [Line Items]
Business acquisitions, number of products purchased																	8			2
Purchase price paid															300,000	[2],[3]				$ 15,300,000
Contingent consideration												$ 5,600,000	[2],[3]		$ 5,600,000	[2],[3]	$ 13,900,000			$ 13,900,000

[1] The BCH segment was created on March 30, 2015 as a result of the Omega acquisition, thus data for the six months ended June 27, 2015 includes only three months of results from operations attributable to Omega.

[2] * Opening balance sheet is preliminary

[3] Consists of one product acquisition in the CHC segment